SONAR
29.5.2024 15:01:32 CEST | Business Wire | Press release
Sonar, the leader in Clean Code solutions, today announced that SonarQube is now available on Google Cloud Marketplace, enabling organizations to accelerate DevOps transformations in the cloud, modernize software development workflows, and deliver higher-quality, secure applications. As companies adopt AI code generation tools, SonarQube ensures that no matter where or how code is developed, it leads to secure, reliable, and maintainable software.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529150627/en/
SonarQube is now available on Google Cloud Marketplace. (Photo: Business Wire)
SonarQube’s availability on Google Cloud Marketplace streamlines the process for developers to identify and address potential issues in code early on in the software development lifecycle (SDLC), whether code is human-developed or AI-generated. Developers can now quickly set up SonarQube in their Google Cloud environment to analyze their code quality with simplified billing and scalability that fit their specific needs and budget. Organizations are empowered to accelerate their DevOps transformation initiatives while minimizing risks and ensuring long-term success.
“Bringing SonarQube to Google Cloud Marketplace will help customers quickly deploy, manage, and grow the solution on Google Cloud's trusted, global infrastructure," said Dai Vu, Managing Director, Marketplace & ISV GTM Programs at Google Cloud. “Sonar can now securely scale and support customers on their digital transformation journeys.”
Google Cloud Marketplace lets users quickly deploy functional software packages that run on Google Cloud's infrastructure. Google Cloud Marketplace allows customers to easily start up a familiar software package with services like Compute Engine or Cloud Storage, with no manual configuration required.
Over the last 15 years, Sonar has analyzed more than half a trillion lines of code across all industries and company sizes, resulting in a deep understanding of how code is written and managed. Sonar evaluates code for quality and security issues at two points - in the IDE with SonarLint, and in the Continuous Integration (CI) pipeline, with SonarQube. Sonar’s offering is built on the principles of Clean Code, which is the belief that when code is consistent, intentional, adaptable, and responsible – meaning it is easy to understand and change, operates smoothly at runtime, and contains no technical debt – it results in software that is maintainable, reliable, of quality, and secure.
“Code is one of the most valuable assets in a digital economy. As companies adopt AI and move to the cloud, we want them to continue having seamless access to Sonar’s Clean Code solutions as part of their DevOps environment in the cloud,” said Harry Wang, VP of Strategic Partnerships & Head of Product Marketing at Sonar. “SonarQube availability on Google Cloud Marketplace means that organizations can easily combine Google’s AI capabilities with the familiar Clean Code solution that they trust, to evolve and accelerate software development safely and responsibly.”
SonarQube is an essential tool in the current DevOps toolchain as it reduces issues before they reach production, reduces rollbacks and rework, increases developer velocity, and increases DevOps efficiency and agility. By preventing new issues from entering into production, software becomes easier to maintain and businesses become more competitive, as new features are faster to add.
Key benefits of its availability on Google Cloud Marketplace include:
- Faster Setup: Get up and running with SonarQube quickly and easily, eliminating the need for complex manual installations.
- Seamless Integration: Developers can incorporate SonarQube into their Google Cloud environment with the ease of container deployment on Google Kubernetes Engine (GKE).
- Scalability: Usage of SonarQube can easily scale with Google Cloud’s infrastructure to match evolving needs, no matter the size of the organization or software project.
- Simplified Billing and Cost Effectiveness: Companies can consolidate the purchase of SonarQube with the rest of their cloud spending to achieve better discounts on Google Cloud and reduce administrative overhead.
To learn more about SonarQube, visit here. SonarQube is generally available now on Google Cloud Marketplace.
About Sonar
Sonar is a leading maker of open source solutions to help developers write Clean Code. Sonar’s solutions — SonarQube, SonarCloud, and SonarLint — support over 30 programming languages, frameworks, and infrastructure technologies. Trusted by more than 400,000 organizations globally to clean more than half a trillion lines of code, Sonar is integral to delivering higher quality, better-performing software.
To learn more about Sonar, please visit https://www.sonarsource.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529150627/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom